BofA analyst Derik de Bruin downgraded Agilent to Neutral from Buy with a price target of $133, up from $130. Shares are up about 13% since the company reported Q4 results on November 20, and valuation appears full, the analyst tells investors in a research note. The firm thinks additional upside is likely limited given the lack of visibility across the life sciences tools market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on A: